RE:RE:My best guessThat would certainly be helpful and perhaps is likely but one would think the majority of any c ash that would change hands in a China partnership would be in the future and as a result of milestones being reached. But whatever upfront payment might be part of such a deal can't hurt.
We still need an equity offering at some point to get analyst coverage for the stock. The lame response in early trading to such a sizable deal tells management just how badly they have mucked up their relationship with the capital markets over the years. But the analysts that purportedly cover TH now just do not have the ability to move the stock price much since their reach is so limited and focused on Canada.
qwerty22 wrote: If th1902 is working you can probably add in a China deal.
So if it's $2 mil deal yesterday. And $100 mil today. Then what tomorrow?
SPCEO1 wrote: So, this financing takes care of the convert ($60 million drawn down by 6/23). But it does not provide funding for any early phase II cancer trials. So, we could still see some equity issuance if TH-1902 does well in phase 1b, which should come at a higher price if TH-1902 shows promise. if not, and it needs to be retooled first, then there may be no need to raise new funds as Egrifta sales are going well and they likely have a 95% gross margin on them, which should provide a lot of money to run the normal operations ex new clinical trials.